ENARA BIO LIMITED

• ⚠

  Material uncertainty over going concern

  Accordingly, the group and the company are reliant on further financing, which is not guaranteed. This indicates that a material uncertainty exists that may cast significant doubt on the group and the company's ability to continue as a going concern, and therefore they may be unable to realise their assets and discharge their liabilities in the normal course of business.

• ◆

  2 PSCs ceased in last 24 months

  Significant control changed hands — see the Ownership section.

1. ENARA BIO LIMITED 2020-06-03 → present
2. ERVAXX LIMITED 2016-11-08 → 2020-06-03

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Accordingly, the group and the company are reliant on further financing, which is not guaranteed. This indicates that a material uncertainty exists that may cast significant doubt on the group and the company's ability to continue as a going concern, and therefore they may be unable to realise their assets and discharge their liabilities in the normal course of business.”

Group structure

1. ENARA BIO LIMITED · parent
   1. Enara Bio Inc. 1% · DE

Significant events

• “In July 2024, a strategic collaboration and licensing agreement to discover novel antigens for cancer immunotherapies with a large pharmaceutical partner was terminated, in line with the changing research priorities of the partner.”
• “In August 2024, a Series B financing subscription agreement (totalling $32.5m) was signed to provide additional financing.”
• “All outstanding convertible loan notes (totalling £2.5m) were converted to equity during the year.”
• “Subsequent to the year end, in January 2025, the second tranche of the Series B financing (£10.6m) from the August 2024 Series B financing subscription agreement was received.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

12

last 12 months

Capital events

13

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -85.3%

  £17,415,246 → £2,565,725

• Cash

  -20.4%

  £11,863,604 → £9,440,036

• Net assets

  +30.4%

  £10,237,013 → £13,352,288

• Employees

  +7.4%

  54 → 58

• Operating profit

  -1,320.7%

  £1,416,102 → -£17,286,888

• Profit before tax

  -1,724.6%

  £1,051,673 → -£17,084,996

• Wages

  +14.3%

  £5,958,094 → £6,811,641

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers